Myelodysplastic Syndromes: all 2,165 studies
Page 16 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic SyndromeStatus unknownNCT01673308Phase 2
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
- 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic SyndromeStatus unknownNCT01652781Phase 2
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesTerminatedNCT01643603Phase 1
- Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeTerminatedNCT01636609Phase 1
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
- Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor CellsTerminatedNCT01624701Phase 1/2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL PilotTerminatedNCT01615146Not applicable
- A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
- INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell TransplantCompletedNCT01602211Phase 3
- Trial of Haploidentical Stem Cell Transplantation for Haematological CancersCompletedNCT01597219Phase 2
- Registry on Hypomethylating Agents in Myeloid NeoplasmsCompletedNCT01595295
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Human Placental-Derived Stem Cell TransplantationCompletedNCT01586455Phase 1
- Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeCompletedNCT01584531Phase 2
- A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic SyndromesCompletedNCT01571648Phase 1
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT01567059Phase 2
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).Status unknownNCT01556477Phase 2
- Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic SyndromeTerminatedNCT01546337
- TevaGastrim for Stem Cell Mobilization Sibling DonorsCompletedNCT01542944Phase 2
- VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT01541280Phase 2
- Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic SyndromeWithdrawnNCT01520805Phase 2
- Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral AzacitidineCompletedNCT01519011Phase 1
- Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
- HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid TumorsStatus unknownNCT01509300Phase 1/2
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic SyndromeCompletedNCT01497145Phase 2
- A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromesCompletedNCT01496495Phase 1
- Administration of Donor T Cells With the Caspase-9 Suicide GeneActive, not recruitingNCT01494103Phase 1
- A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for ThrombocytopeniaCompletedNCT01488565Phase 2
- Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell TransplantsTerminatedNCT01488253Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)CompletedNCT01481220Phase 1
- Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01463046Phase 1
- Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)CompletedNCT01462578Phase 2
- Study of (Telintra®) in Non-Del(5q) Myelodysplastic SyndromeTerminatedNCT01459159Phase 2
- PRO#0118: Decitabine Plus Mini Flu-BuCompletedNCT01455506Phase 1
- Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)Status unknownNCT01451268Phase 1/2
- Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT01433965Phase 1
- Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)CompletedNCT01422603Phase 1/2
- Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic SyndromeTerminatedNCT01422486Phase 2
- Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDSStatus unknownNCT01417767Phase 2/3
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesCompletedNCT01413568Phase 1/2
- Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic SyndromeCompletedNCT01409070
- 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)CompletedNCT01404741Phase 2
- An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01400633
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1
- Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia PatientsCompletedNCT01398462Phase 1
- Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell TransplantCompletedNCT01390311Phase 1
- NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT01386619Phase 1/2
- Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)CompletedNCT01385423Phase 1
- An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic SyndromesCompletedNCT01381809Phase 3
- Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
- Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of PlerixaforCompletedNCT01362985
- Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and ThrombocytopeniaTerminatedNCT01362036Phase 1
- Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive ChemotherapyStatus unknownNCT01356875Phase 2
- Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+CellsCompletedNCT01355913
- MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National RegistryCompletedNCT01347944
- Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic SyndromesStatus unknownNCT01342692Phase 2
- Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation CyclophosphamideCompletedNCT01342289Phase 1
- Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Status unknownNCT01339988Phase 4
- Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent AnaemiaCompletedNCT01338337Phase 2
- Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS PatientsTerminatedNCT01333449Phase 2
- Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary MyelofibrosisStatus unknownNCT01331603
- Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic SyndromesWithdrawnNCT01324960Phase 1/2
- Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic SyndromeCompletedNCT01314599Phase 1
- Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT01305460Phase 1/2
- Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic SyndromesCompletedNCT01305135Phase 1/2
- Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic SyndromesWithdrawnNCT01302106Phase 2
- TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTerminatedNCT01300611Phase 1
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for LeukemiaCompletedNCT01297543Phase 1/2
- Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMESStatus unknownNCT01291745
- Empirical Versus Preemptive Antifungal TherapyCompletedNCT01288378Phase 3
- Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With ThrombocytopeniaTerminatedNCT01286038Phase 1
- Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AMLStatus unknownNCT01277484Phase 1
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
- Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)Status unknownNCT01255319
- Reduced-intensity Conditioning Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01252784
- This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
- Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal DiseaseCompletedNCT01249820Phase 2
- Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic SyndromeCompletedNCT01243476Phase 3
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedNCT01241500Phase 3
- High-Tc Susceptometer to Monitor Transfusional Iron OverloadCompletedNCT01241357
- Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological CancersStatus unknownNCT01240525Phase 2
- A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.CompletedNCT01236144Phase 1/2
- Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyCompletedNCT01235572Phase 2
- Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological DisordersCompletedNCT01224496Phase 1/2
- Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)SuspendedNCT01211691Phase 1/2
- Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Status unknownNCT01211457Phase 1/2
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- Dose-reduced Versus Standard Conditioning in MDS/sAMLTerminatedNCT01203228Phase 3
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT01200017
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic SyndromesCompletedNCT01196715Phase 3
- Non-interventional Study With Azacitidin (Vidaza®)CompletedNCT01192945
- Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure SyndromesCompletedNCT01192425